Iliana Stamatiou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iliana Stamatiou has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Ioannis Kotsianidis
Department of Haematology University Hospital of Alexandroupolis, Democritus University of Thrace Alexandroupolis Greece
6 shared publicationsZoe Bezirgiannidou
Department of Haematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
4 shared publicationsEmmanouil Spanoudakis
Department of Haematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
3 shared publicationsKonstantinos Liapis
Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
3 shared publications- Konstantinos Liapis
Department of Haematology Democritus University of Thrace Medical School Alexandroupolis Greece
3 shared publications - Bouse Malkots
Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2335-2340
The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2335-2340
Open AccessThe role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes
- Open Access
Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta‐analysis
The authors performed a systematic review and meta‐analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high‐income and low‐income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient‐centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
Open AccessExcess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta‐analysis
The authors performed a systematic review and meta‐analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high‐income and low‐income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient‐centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
- Open Access
- 1 June 2026
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 37 (2) , 431-436
Post–EBV Cold Urticaria with High-Titre Cold Agglutinins without Haemolysis: A Paediatric Case Report
This report describes a paediatric case of cold urticaria (ColdU) associated with markedly elevated cold agglutinin titres following Epstein–Barr virus (EBV) infection. An 11-year-old girl developed recurrent cold-induced urticaria and anaphylaxis after a recent EBV infection. Immunohaematologic testing revealed a cold-reactive IgM autoantibody with anti-i specificity. Despite the exceptionally high peak titres (>1:262,144 at 4°C), and the unusually broad thermal amplitude extending to 30°C, no clinical or laboratory evidence of haemolysis was observed, and the direct antiglobulin test remained persistently negative. Complement components and cryoprotein assays were consistently normal. Throughout an extended 52-month longitudinal follow-up, antibody titres gradually declined in parallel with the resolution of urticarial symptoms and withdrawal of antihistamines. This case demonstrates a non-haemolytic, post-infectious immune phenotype of ColdU, in which transient, high-titre cold agglutinins coexist with cutaneous hypersensitivity without haemolytic manifestations, and highlights the importance of comprehensive immunohaematologic evaluation and long-term monitoring in ColdU cases with atypical serologic findings. Cite this article as: Bezirgiannidou Z, Stamatiou I, Spanopoulou C, Mavroudi A, Kitsos N, Spanoudakis E, Kotsianidis I, Cassimos D. Post–EBV Cold Urticaria with High-Titre Cold Agglutinins without Haemolysis: A Paediatric Case Report. Mediterr J Rheumatol 2026;Mediterr J Rheumatol 2026;37(2):431-436. Article Submitted: 22 Oct 2025; Revised Form: 31 Jan 2026; Article Accepted: 12 Feb 2026; Available Online: 1 Jun 2026 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2026 The Author(s). https://doi.org/10.31138/mjr.221025.rcu
- 1 June 2026
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 37 (2) , 431-436
Open AccessPost–EBV Cold Urticaria with High-Titre Cold Agglutinins without Haemolysis: A Paediatric Case Report
This report describes a paediatric case of cold urticaria (ColdU) associated with markedly elevated cold agglutinin titres following Epstein–Barr virus (EBV) infection. An 11-year-old girl developed recurrent cold-induced urticaria and anaphylaxis after a recent EBV infection. Immunohaematologic testing revealed a cold-reactive IgM autoantibody with anti-i specificity. Despite the exceptionally high peak titres (>1:262,144 at 4°C), and the unusually broad thermal amplitude extending to 30°C, no clinical or laboratory evidence of haemolysis was observed, and the direct antiglobulin test remained persistently negative. Complement components and cryoprotein assays were consistently normal. Throughout an extended 52-month longitudinal follow-up, antibody titres gradually declined in parallel with the resolution of urticarial symptoms and withdrawal of antihistamines. This case demonstrates a non-haemolytic, post-infectious immune phenotype of ColdU, in which transient, high-titre cold agglutinins coexist with cutaneous hypersensitivity without haemolytic manifestations, and highlights the importance of comprehensive immunohaematologic evaluation and long-term monitoring in ColdU cases with atypical serologic findings. Cite this article as: Bezirgiannidou Z, Stamatiou I, Spanopoulou C, Mavroudi A, Kitsos N, Spanoudakis E, Kotsianidis I, Cassimos D. Post–EBV Cold Urticaria with High-Titre Cold Agglutinins without Haemolysis: A Paediatric Case Report. Mediterr J Rheumatol 2026;Mediterr J Rheumatol 2026;37(2):431-436. Article Submitted: 22 Oct 2025; Revised Form: 31 Jan 2026; Article Accepted: 12 Feb 2026; Available Online: 1 Jun 2026 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2026 The Author(s). https://doi.org/10.31138/mjr.221025.rcu
- Open Access
Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation
Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.
Open AccessClonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation
Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.
- Open Access
- 25 February 2026
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 134 (04) , 124-128
Diabetic Ulnar Compression Neuropathy
Ulnar compression neuropathy is the second most frequent entrapment neuropathy of the upper extremity and is observed with increased prevalence among diabetes mellitus patients. The metabolic burden of diabetes mellitus, including chronic hyperglycaemia, microvascular dysfunction, and systemic inflammation, promotes nerve susceptibility to mechanical compression. This review summarises current evidence on the association between diabetes mellitus and ulnar compression neuropathy, highlighting epidemiological data, metabolic contributors, clinical manifestations, diagnostic tools, and management strategies. Diagnostic evaluation in diabetes mellitus patients may be challenging due to coexisting polyneuropathy, necessitating a multimodal and individualized approach. Management strategies include both conservative measures and surgical decompression, with early intervention being critical to prevent permanent deficits. Clinicians should maintain high suspicion of ulnar compression neuropathy in diabetes mellitus patients to ensure timely diagnosis and improve functional outcomes in this high-risk population.
- 25 February 2026
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 134 (04) , 124-128
Open AccessDiabetic Ulnar Compression Neuropathy
Ulnar compression neuropathy is the second most frequent entrapment neuropathy of the upper extremity and is observed with increased prevalence among diabetes mellitus patients. The metabolic burden of diabetes mellitus, including chronic hyperglycaemia, microvascular dysfunction, and systemic inflammation, promotes nerve susceptibility to mechanical compression. This review summarises current evidence on the association between diabetes mellitus and ulnar compression neuropathy, highlighting epidemiological data, metabolic contributors, clinical manifestations, diagnostic tools, and management strategies. Diagnostic evaluation in diabetes mellitus patients may be challenging due to coexisting polyneuropathy, necessitating a multimodal and individualized approach. Management strategies include both conservative measures and surgical decompression, with early intervention being critical to prevent permanent deficits. Clinicians should maintain high suspicion of ulnar compression neuropathy in diabetes mellitus patients to ensure timely diagnosis and improve functional outcomes in this high-risk population.
- Open Access
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Aging as a Potential Modulator of Extramedullary Hematopoiesis: A Hypothesis-Generating Niche-HSPC Competence-Trigger Model
Extramedullary hematopoiesis (EMH) is a compensatory response to hematopoietic stress that occurs unevenly across disorders with ineffective erythropoiesis (IE). The mechanisms underlying differing EMH patterns despite similarly severe IE remain poorly understood. Thalassemia and congenital dyserythropoietic anemias frequently develop overt EMH, whereas myelodysplastic syndromes (MDS), despite severe IE, rarely show overt EMH. We propose the Niche-HSPC Competence-Trigger Model as a hypothesis-generating framework in which EMH expression reflects the interaction among erythropoietic trigger load, intrinsic hematopoietic stem and progenitor cell (HSPC) competence, and extramedullary niche fitness. Erythropoietic trigger load reflects the intensity and persistence of erythropoietic stress, particularly anemia and hypoxia, in disorders characterized by ineffective erythropoiesis. HSPC competence refers to the intrinsic capacity of HSPCs for proliferation and differentiation, whereas extramedullary niche fitness denotes the capacity of target tissues to support HSPC homing, engraftment, survival, expansion, and productive hematopoiesis; this capacity is shaped by stromal and vascular integrity, inflammatory and fibrotic remodeling, metabolic support, and iron availability. Within this framework, overt EMH is hypothesized to be favored when erythropoietic drive coincides with preserved HSPC competence and extramedullary niche fitness. Conversely, impaired HSPC competence or reduced niche fitness may limit overt EMH, while whether subclinical extramedullary hematopoietic activity occurs in MDS remains unresolved. We hypothesize that aging may modulate this balance by influencing both HSPC competence and niche fitness, thereby potentially contributing to the rarity of overt EMH in MDS. These hypotheses, including the contribution of aging and the possible occurrence of subclinical extramedullary hematopoietic activity, require experimental and clinical validation.
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Open AccessAging as a Potential Modulator of Extramedullary Hematopoiesis: A Hypothesis-Generating Niche-HSPC Competence-Trigger Model
Extramedullary hematopoiesis (EMH) is a compensatory response to hematopoietic stress that occurs unevenly across disorders with ineffective erythropoiesis (IE). The mechanisms underlying differing EMH patterns despite similarly severe IE remain poorly understood. Thalassemia and congenital dyserythropoietic anemias frequently develop overt EMH, whereas myelodysplastic syndromes (MDS), despite severe IE, rarely show overt EMH. We propose the Niche-HSPC Competence-Trigger Model as a hypothesis-generating framework in which EMH expression reflects the interaction among erythropoietic trigger load, intrinsic hematopoietic stem and progenitor cell (HSPC) competence, and extramedullary niche fitness. Erythropoietic trigger load reflects the intensity and persistence of erythropoietic stress, particularly anemia and hypoxia, in disorders characterized by ineffective erythropoiesis. HSPC competence refers to the intrinsic capacity of HSPCs for proliferation and differentiation, whereas extramedullary niche fitness denotes the capacity of target tissues to support HSPC homing, engraftment, survival, expansion, and productive hematopoiesis; this capacity is shaped by stromal and vascular integrity, inflammatory and fibrotic remodeling, metabolic support, and iron availability. Within this framework, overt EMH is hypothesized to be favored when erythropoietic drive coincides with preserved HSPC competence and extramedullary niche fitness. Conversely, impaired HSPC competence or reduced niche fitness may limit overt EMH, while whether subclinical extramedullary hematopoietic activity occurs in MDS remains unresolved. We hypothesize that aging may modulate this balance by influencing both HSPC competence and niche fitness, thereby potentially contributing to the rarity of overt EMH in MDS. These hypotheses, including the contribution of aging and the possible occurrence of subclinical extramedullary hematopoietic activity, require experimental and clinical validation.
- Open Access
A 74-Year-Old Man with Massive Ascites: A Case Report of Yellow Nail Syndrome
Background and clinical significance: Lymphedema is a relatively common clinical manifestation in patients and has a broad differential diagnosis, the main concern being the exclusion of malignancy. However, a rare constellation of lymphedema with systemic features and no underlying malignancy is yellow nail syndrome (YNS). YNS is a lymphatic abnormality, characterized by a triad of yellow nails, primary lymphedema and respiratory manifestations. Case presentation: Here, we report a 74-year-old male patient who presented to us with massive chylous ascites, cough, yellow nails and recurrent bilateral leg edema. During the last 10 years, he had thrice undergone thoracocentesis, which revealed chylous pleural effusion, although there was no documented diagnosis of yellow nail syndrome. We pursued a thorough work-up to rule out underlying cirrhosis and malignancy (the main causes of chylous ascites). There are only few cases of yellow nail syndrome reported in the literature with chylous ascites as a manifestation of YNS. Conclusions: The co-existence of chylous ascites with the classical triad of pleural effusion, lymphedema and yellow nail changes in the same patient has to be included in the diagnostic process to differentiate this entity from liver cirrhosis and solid or hematological cancer.
Open AccessA 74-Year-Old Man with Massive Ascites: A Case Report of Yellow Nail Syndrome
Background and clinical significance: Lymphedema is a relatively common clinical manifestation in patients and has a broad differential diagnosis, the main concern being the exclusion of malignancy. However, a rare constellation of lymphedema with systemic features and no underlying malignancy is yellow nail syndrome (YNS). YNS is a lymphatic abnormality, characterized by a triad of yellow nails, primary lymphedema and respiratory manifestations. Case presentation: Here, we report a 74-year-old male patient who presented to us with massive chylous ascites, cough, yellow nails and recurrent bilateral leg edema. During the last 10 years, he had thrice undergone thoracocentesis, which revealed chylous pleural effusion, although there was no documented diagnosis of yellow nail syndrome. We pursued a thorough work-up to rule out underlying cirrhosis and malignancy (the main causes of chylous ascites). There are only few cases of yellow nail syndrome reported in the literature with chylous ascites as a manifestation of YNS. Conclusions: The co-existence of chylous ascites with the classical triad of pleural effusion, lymphedema and yellow nail changes in the same patient has to be included in the diagnostic process to differentiate this entity from liver cirrhosis and solid or hematological cancer.
- Open Access
- 28 August 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (9) , 4849-4854
Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration
This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.
- 28 August 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (9) , 4849-4854
Open AccessRavulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration
This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.
- Open Access
- 15 July 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 141, 106407
Deterioration of renal function is delayed in patients with atrial fibrillation treated with direct oral anticoagulants compared to vitamin K antagonists: systematic review and meta-analysis
- 15 July 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 141, 106407
Open AccessDeterioration of renal function is delayed in patients with atrial fibrillation treated with direct oral anticoagulants compared to vitamin K antagonists: systematic review and meta-analysis
- Open Access
- 16 December 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (6) , 1076-1077
Pseudothrombocytopenia due to Phagocytosis of Platelets by Polymorphonuclear Leukocytes
- 16 December 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (6) , 1076-1077
Open AccessPseudothrombocytopenia due to Phagocytosis of Platelets by Polymorphonuclear Leukocytes